The Company has initiated an executive search for this position and, on interim basis, Christopher Reinhard, the company’s executive chairman will assume executive responsibilities for the operations of the company. Ms Goostree also resigned from her position as a director on the company’s board of directors.
In connection with this announcement, during this transition period, John Kay, the company’s vice president of engineering and development research will assume responsibilities for the coordination of product development and manufacturing activities, working with Larry Braga, vice president of manufacturing.
In addition, Karon Morell, vice president of regulatory and quality affairs, will now also be responsible for the management and coordination of the company’s ongoing clinical studies working with Greg Kricorian, chief medical officer. Michael Green, CFO will assume responsibility for the company’s overall day-to-day administrative activities.
Mr Reinhard, said: “During her tenure, Diane played an important role in leading Artes Medical through the navigation of some important challenges, including the complex regulatory process and FDA approval of ArteFill, the first and only non-resorbable injectable wrinkle filler, as well as transitioning the company through the going-public process.”